Suppr超能文献

对患者常规给药期间维拉帕米蓄积原因的调查。

An investigation of the cause of accumulation of verapamil during regular dosing in patients.

作者信息

Schwartz J B, Abernethy D R, Taylor A A, Mitchell J R

出版信息

Br J Clin Pharmacol. 1985 Apr;19(4):512-6. doi: 10.1111/j.1365-2125.1985.tb02678.x.

Abstract

The accumulation of verapamil during regular dosing conditions was studied. Plasma concentrations of verapamil (V) and norverapamil (NV) were measured as were urinary concentrations of verapamil, norverapamil, and four other N- and O-dealkylated metabolites in nine patients after an initial single dose and after chronic oral verapamil administration to steady-state plasma concentrations. Indocyanine green (ICG) clearance was determined immediately prior to the initial verapamil dose and prior to the verapamil washout from regular dosing. An approximately two-fold accumulation of V had occurred during regular dosing. The area under the plasma concentration-time curve (AUC1) after the first dose was 417.4 +/- 276.7 ng ml-1 h (mean +/- s.d.) and increased to 786.5 +/- 54 ng ml-1 h (P less than 0.01) during one dosage interval at steady-state (AUCss). NV also tended to accumulate from an AUC1 of 552.6 +/- 411 to an AUCss 668.7 +/- 332 ng ml-1 h (P less than 0.09). The ratio of AUC-V to AUC-NV was unchanged. The verapamil elimination half-life (t 1/2) increased from 8.4 +/- 4.2 to 12.0 +/- 3.6 h (P less than 0.01) whereas the norverapamil t 1/2 was unchanged. ICG clearance was unchanged. Urinary excretion of NV increased slightly but the ratio of urinary V/NV concentrations was not significantly altered nor was the ratio of four other metabolites to verapamil or the ratio of the combined o-demethylated to the N-dealkylated metabolites.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

研究了常规给药条件下维拉帕米的蓄积情况。在9名患者单次初始给药后以及慢性口服维拉帕米至稳态血药浓度后,测定了维拉帕米(V)和去甲维拉帕米(NV)的血浆浓度,以及维拉帕米、去甲维拉帕米和其他4种N - 去烷基化和O - 去烷基化代谢物的尿浓度。在初始维拉帕米给药前以及常规给药的维拉帕米清除前,测定了吲哚菁绿(ICG)清除率。常规给药期间V出现了约2倍的蓄积。首剂后的血浆浓度 - 时间曲线下面积(AUC1)为417.4±276.7 ng·ml⁻¹·h(均值±标准差),在稳态时的一个给药间隔期间(AUCss)增至786.5±54 ng·ml⁻¹·h(P<0.01)。NV也有蓄积倾向,AUC1为552.6±411,AUCss为668.7±332 ng·ml⁻¹·h(P<0.09)。AUC - V与AUC - NV的比值未变。维拉帕米消除半衰期(t₁/₂)从8.4±4.2小时增至12.0±3.6小时(P<0.01),而去甲维拉帕米的t₁/₂未变。ICG清除率未变。NV的尿排泄略有增加,但尿中V/NV浓度比值未显著改变,其他4种代谢物与维拉帕米的比值以及O - 去甲基化代谢物与N - 去烷基化代谢物的合并比值也未改变。(摘要截短于250词)

相似文献

7
In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil.
Clin Pharmacol Ther. 1999 Jul;66(1):40-50. doi: 10.1016/S0009-9236(99)70052-4.
8
Pharmacokinetics of verapamil and norverapamil during long-term oral therapy.
Res Commun Chem Pathol Pharmacol. 1983 Apr;40(1):15-27.

引用本文的文献

2
The effect of oral verapamil therapy on antipyrine clearance.口服维拉帕米疗法对安替比林清除率的影响。
Br J Clin Pharmacol. 1986 Nov;22(5):606-9. doi: 10.1111/j.1365-2125.1986.tb02942.x.
3
Verapamil pharmacokinetics.维拉帕米的药代动力学。
Br J Clin Pharmacol. 1986 May;21(5):554-5. doi: 10.1111/j.1365-2125.1986.tb02846.x.
5
6
Pharmacokinetics of calcium antagonists under development.正在研发的钙拮抗剂的药代动力学。
Clin Pharmacokinet. 1988 Jul;15(1):1-14. doi: 10.2165/00003088-198815010-00001.

本文引用的文献

8
Prediction of steady-state verapamil plasma concentrations in children and adults.
Clin Pharmacol Ther. 1982 Aug;32(2):172-81. doi: 10.1038/clpt.1982.144.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验